FDA Asks Rocket for More Data on Kresladi Gene Therapy
The FDA has issued a complete response letter (CRL) to Rocket Pharmaceuticals requesting additional chemistry, manufacturing and controls (CMC) information before reviewing the company’s BLA for Kresladi (marnetegragene autotemcel).
Source: Drug Industry Daily